Boston Scientific Corp (NYSE: BSX) on Friday, plunged -0.48% from the previous trading day, before settling in for the closing price of $84.02. Within the past 52 weeks, BSX’s price has moved between $50.84 and $88.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 8.10%. The company achieved an average annual earnings per share of 20.04%. With a float of $1.47 billion, this company’s outstanding shares have now reached $1.47 billion.
Considering the fact that the conglomerate employs 48000 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 67.3%, operating margin of 17.23%, and the pretax margin is 13.84%.
Boston Scientific Corp (BSX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Boston Scientific Corp is 0.43%, while institutional ownership is 91.95%. The most recent insider transaction that took place on Nov 01 ’24, was worth 588,876. Before that another transaction happened on Oct 07 ’24, when Company’s Chairman, President & CEO sold 162,777 for $84.63, making the entire transaction worth $13,775,792. This insider now owns 1,572,096 shares in total.
Boston Scientific Corp (BSX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 20.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.20% during the next five years compared to -2.05% drop over the previous five years of trading.
Boston Scientific Corp (NYSE: BSX) Trading Performance Indicators
Boston Scientific Corp (BSX) is currently performing well based on its current performance indicators. A quick ratio of 1.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.70. Likewise, its price to free cash flow for the trailing twelve months is 56.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.21, a number that is poised to hit 0.65 in the next quarter and is forecasted to reach 2.79 in one year’s time.
Technical Analysis of Boston Scientific Corp (BSX)
Compared to the last year’s volume of 6.11 million, its volume of 8.57 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 39.85%. Additionally, its Average True Range was 1.78.
During the past 100 days, Boston Scientific Corp’s (BSX) raw stochastic average was set at 69.43%, which indicates a significant increase from 36.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 14.64% in the past 14 days, which was lower than the 16.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $83.94, while its 200-day Moving Average is $74.63. Nevertheless, the first resistance level for the watch stands at $84.43 in the near term. At $85.24, the stock is likely to face the second major resistance level. The third major resistance level sits at $85.70. If the price goes on to break the first support level at $83.15, it is likely to go to the next support level at $82.69. Now, if the price goes above the second support level, the third support stands at $81.88.
Boston Scientific Corp (NYSE: BSX) Key Stats
Market capitalization of the company is 122.55 billion based on 1,472,626K outstanding shares. Right now, sales total 14,240 M and income totals 1,591 M. The company made 4,209 M in profit during its latest quarter, and 468,000 K in sales during its previous quarter.
